.: Zeltia S.A. : Yondelis® Has Been Helping Patients With STS For The Last 5 Years .

CAMBIO DE DISCURSO : LA SECOND-LINE SCLC-ES TRAS EL FIASCO DE LA FASE III LAGOON YA MEJOR NI NOMBRARLA...CAMBIAMOS DISCURSO A MANTENIMIENTO EN FIRTS-LINE Y PASAMOS DEL VIAL DE 4 Mg AI VIAL DE 2 Mg .//. JazzPharma TO WITHDRAW LURBINECTEDIN WITH US_FDA IN SECOND-LINE SCLC-ES...EN ESPAÑA NO SE HAN ENTERADO AÚN...SI NO EXISTIERA IMFORTE...AHORA MISMO PHARMAMAR ESTARÍA ANTE UNA GRAVE SITUACIÓN ... 2 DE OCTUBRE DE 2028 ... ES LA FECHA MÁS TEPMPRANA PARA LA POSIBLE ENTRADA DE GENÉRICOS .

15 noviembre 2012

Zeltia S.A. : Yondelis® Has Been Helping Patients With STS For The Last 5 Years .

PharmaMar representatives will mark the 5th anniversary of Yondelis® from the authorization of the European Commission at the 17th CTOS (Connective Tissue Oncology Society) annual meeting, which will be held in Prague between 14th and 17th November.

During these five years, more than 12,000 patients around the world were treated with this product.

At the congress there will be a total of 18 publications reporting results of the treatment of advanced STS with Yondelis®.

...